Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
5-Year IF – 2.0, IF – 1.9, JCI (2024) – 0.43
Scopus CiteScore – 4.3
Q1 in SJR 2024, SJR score – 0.598, H-index: 49 (SJR)
ICV – 161.00; MNiSW – 70 pts
Initial editorial assessment and first decision within 24 h

ISSN 1899–5276 (print), ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2018, vol. 27, nr 4, April, p. 441–447

doi: 10.17219/acem/68387

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Decoy receptor 3 alleviates hepatic fibrosis through suppressing inflammation activated by NF-κB signaling pathway

Zhenjing Jin1,A,E, Siqi Liu1,B,C, Qian Zhang1,D,E, Xue Shao1,B,F, Jingting Ma1,C,F, Liulan Pan1,D,E,F

1 The Second Clinical Hospital, Jilin University, Changchun, China

Abstract

Background. Hepatic fibrosis is a reversible pathological process. Inflammatory responses are the prevailing reactions during hepatic fibrosis. Decoy receptor 3 (DcR3) has been reported to have an anti-inflammatory effect.
Objectives. The aim of the study was to investigate the preventive effects of DcR3 on hepatic fibrosis.
Material and Methods. Hepatic fibrosis was induced in rats by administering intraperitoneally (ip.) 1% dimethylnitrosamine (DMN). DcR3 plasmid was delivered into rats by intravenous injection. After 4 weeks, the expression of DcR3, TNF-like molecule 1A (TL1A) and α-SMA of the liver tissue were checked. The levels of inflammatory cytokines such as TNF-α, IL-6 and IL-1β were detected using western blotting and quantitative real-time reverse transcription-polymerase chain reaction (qRT-PCR). Masson’s trichrome staining for histopathological changes of the liver tissue was observed. Finally, the activity of NF-κB in the liver was examined by enzyme-linked immunosorbent assay (ELISA).
Results. A higher expression of DcR3 was observed in rats treated with DcR3 (p < 0.05). Histological results showed that DcR3 significantly attenuated pathology in hepatic fibrosis rats. Consistently, mRNA and protein levels of α-SMA, TL1A, TNF-α, IL-6, and IL-1β were repressed in the liver tissue after treatment with DcR3 (p < 0.05). Moreover, DcR3 also inhibited the activation of NF-κB in the liver tissue (p < 0.05).
Conclusion. This study demonstrated that DcR3 attenuated liver injury and inflammatory responses in rats with hepatic fibrosis. We suggest DcR3 may be a prophylactic and promising therapeutic agent in the treatment of hepatic fibrosis.

Key words

decoy receptor 3, hepatic fibrosis, inflammatory response, NF-κB, TNF-like molecule 1A

References (26)

  1. Safer AM, Afzal M, Hanafy N, Mousa S. Green tea extract therapy diminishes hepatic fibrosis mediated by dual exposure to carbon tetrachloride and ethanol: A histopathological study. Experimental and Therapeutic Medicine. 2015;9:787–794.
  2. Simpson KJ, Lukacs NW, Colletti L, Strieter RM, Kunkel SL. Cytokines and the liver. J Hepatol. 1997;27:1120–1132.
  3. Iredale J. Defining therapeutic targets for liver fibrosis: Exploiting the biology of inflammation and repair. Pharmacological Research. 2008;58:129–136.
  4. Imajo K, Kessoku T, Honda Y, et al. Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalco- holic fatty liver disease than transient elastography. Gastroenterology. 2016;150:626–637.e7.
  5. Chen P, Li J, Huo Y, et al. Orphan nuclear receptor NR4A2 inhibits hepatic stellate cell proliferation through MAPK pathway in liver fibrosis. Peer J. 2015;3:1518.
  6. Alcolado R, Arthur MJ, Iredale JP. Pathogenesis of liver fibrosis. Clin Sci (Lond). 1997;92:103–112.
  7. Ashkenazi A. Targeting death and decoy receptors of the tumournecrosis factor superfamily. Nature Reviews Cancer. 2002;2:420–430.
  8. Bai C, Connolly B, Metzker ML, et al. Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplifi- cation and its location in a four-gene cluster. Proc Natl Acad Sci U S A. 2000;97:1230–1235.
  9. Pitti RM, Marsters SA, Lawrence DA, et al. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature. 1998;396:699–703.
  10. Migone TS, Zhang J, Luo X, et al. TL1A is a TNF–like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity. 2002;16:479–492.
  11. Yu KY, Kwon B, Ni J, Zhai Y, Ebner R, Kwon BS. A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppress- es LIGHT-mediated apoptosis. J Biol Chem. 1999;274:13733–13736.
  12. Liu YJ, Shao LH, Zhang J, et al. The combination of decoy receptor 3 and soluble triggering receptor expressed on myeloid cells-1 for the diagnosis of nosocomial bacterial meningitis. Ann Clin Microbi- ol Antimicrob. 2015;14:17.
  13. Shi G, Luo H, Wan X, Salcedo TW, Zhang J, Wu J. Mouse T cells receive costimulatory signals from LIGHT, a TNF family member. Blood. 2002;100:3279–3286.
  14. Liang D, Hou Y, Lou X, Chen H. Decoy receptor 3 improves survival in experimental sepsis by suppressing the inflammatory response and lymphocyte apoptosis. PLoS One. 2015;10:0131680.
  15. Huang ZM, Kang JK, Chen CY, et al. Decoy receptor 3 suppresses TLR2–mediated B cell activation by targeting NF-kappaB. J Immu- nol. 2012;188:5867–5876.
  16. Shu M, Huang DD, Hung ZA, Hu XR, Zhang S. Inhibition of MAPK and NF-kappaB signaling pathways alleviate carbon tetrachloride (CCl4)- induced liver fibrosis in Toll-like receptor 5 (TLR5) deficiency mice. Biochem Biophys Res Commun. 2016;471:233–239.
  17. Huang MT, Chen ST, Wu HY, Chen YJ, Chou TY, Hsieh SL. DcR3 suppresses influenza virus-induced macrophage activation and attenu- ates pulmonary inflammation and lethality. J Mol Med. 2015;93:1131–1143.
  18. Ka SM, Sytwu HK, Chang DM, Hsieh SL, Tsai PY, Chen A. Decoy receptor 3 ameliorates an autoimmune crescentic glomerulonephritis model in mice. J Am Soc Nephrol. 2007;18:2473–2485.
  19. Hernandez-Gea V, Friedman SL. Pathogenesis of liver fibrosis. Annu Rev Pathol. 2011;6:425–456.
  20. Tacke F, Weiskirchen R. Liver fibrosis – pathogenesis and novel therapeutic approaches. Internist (Berl). 2010;51:21–29 [in German].
  21. Gangadharan B, Antrobus R, Chittenden D, et al. New approaches for biomarker discovery: The search for liver fibrosis markers in hep- atitis C patients. Journal of Proteome Research. 2011;10:2643–2650.
  22. Shin DS, Kim KW, Chung HY, Yoon S, Moon JO. Effect of sinapic acid against carbon tetrachloride-induced acute hepatic injury in rats. Archives of Pharmacol Research. 2013;36:626–633.
  23. Gao B, Jeong WI, Tian Z. Liver: An organ with predominant innate immunity. Hepatology. 2008;47:729–736.
  24. da Silva KA, Paszcuk AF, Passos GF, et al. Activation of cannabinoid receptors by the pentacyclic triterpene alpha, beta-amyrin inhibits inflammatory and neuropathic persistent pain in mice. Pain. 2011;152:1872–1887.
  25. Ma Z, Wang B, Wang M, et al. TL1A increased IL-6 production on fibroblast-like synoviocytes by preferentially activating TNF receptor 2 in rheumatoid arthritis. Cytokine. 2016;83:92–98.
  26. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterolo- gy. 2008;134:1655–1669.
© Wroclaw Medical University